FBLG - Rasio utang marang kapitalisasi buku fibrobiologics.com

Tandha merek fibrobiologics.com (FBLG)

FibroBiologics, Inc. (FBLG) ensures a seamless flow of bioreactors through diversified express delivery channels. The business's environmental sustainability is supported by energy-efficient biomaterial storage and safe disposal. Development relies on cell cultivation methods for the therapy of psoriasis and sclerosis. The trajectory of the company's financial leverage demonstrates borrowing dynamics, where 0.32 is recorded as the baseline value.

FBLG (FibroBiologics) riwayat Utang marang nilai buku saka 21.02.2024 nganti 28.10.2026

fibrobiologics.com (FBLG) - rincian metrik lan laporan keuangan

- rega lan prakiraan konsensus rega:
Rega saham FibroBiologics|FBLG - Rata-rata rega prakiraan
- data kapitalisasi pasar:
Nilai pasar FibroBiologics, Inc.|FBLG - Rega Nyata Tumbas Perusahaan Kanthi Wutuh
- data kapitalisasi buku:
Nilai Buku saben Saham FibroBiologics|FBLG - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku fibrobiologics.com|FBLG - Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas FibroBiologics, Inc.|FBLG - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas FibroBiologics|FBLG - Utang perusahaan|Rasio utang marang kapitalisasi buku FibroBiologics, Inc.
Ringkesan analitik perusahaan:FibroBiologics Corp
Produk asli FibroBiologics

Controlling leverage levels is critical for minimizing risks in long-term investing. The specifics of regenerative medicine at FibroBiologics, Inc. (FBLG) require significant expenditures on fibroblast research. By analyzing the ratio of debt obligations to book capitalization, an investor assesses the share of loans within the company's total capital. An increase in this ratio signals rising debt service costs, while the stability of this metric confirms the financial resilience of the innovative business.

Pesaing FibroBiologics, Inc.

MESO: Utang-utang marang kapitalisasi buku|lineagecell.com - Utang-utang marang nilai buku|SRZN: Rasio utang marang kapitalisasi buku|CCEL - Utang marang nilai buku|LGVN (Longeveron Corp) - Utang-utang marang kapitalisasi buku|BioRestorative Therapies, Inc. (BRTX) - Utang marang nilai buku|Utang-utang marang kapitalisasi buku CELZ (Creative Medical Technology Holdings, Inc.)